Sanofi (SNY) Tax Provisions (2009 - 2026)

Sanofi has disclosed Tax Provisions across 18 years of filings, most recently posting -$491.7 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at -$491.7 million, up 2.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.6 billion (down 26.5% YoY), and the FY2025 annual result was $1.2 billion, down 5.63% from the prior year.
• Tax Provisions came in at -$491.7 million for Q1 2026 at Sanofi, up from -$1.2 billion in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of -$113.0 million in Q1 2024 to a low of -$2.0 billion in Q4 2022.
• The 5-year median for Tax Provisions is -$506.0 million (2025), against an average of -$720.0 million.
• Across the five-year window, Tax Provisions sank 567.55% in 2022 and soared 77.07% in 2024, its largest moves.
• Sanofi's Tax Provisions stood at -$2.0 billion in 2022, then soared by 46.53% to -$1.1 billion in 2023, then decreased by 17.58% to -$1.3 billion in 2024, then increased by 5.63% to -$1.2 billion in 2025, then jumped by 59.5% to -$491.7 million in 2026.
• The last three Tax Provisions figures came in at -$491.7 million (Q1 2026), -$1.2 billion (Q4 2025), and -$1.6 billion (Q3 2025), per Business Quant data.